Forgot Your Password?
Complete Story

Immunization Updates

Immunization - Vaccine Updates

(Last updated 08/20/2014)

CDC publishes 2014–15 influenza vaccination recommendations in MMWR

CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014–15 Influenza Season in the August 15 issue of MMWR. The first paragraph of the report is reprinted below.

This report updates the 2013 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding use of seasonal influenza vaccines. Updated information for the 2014–15 influenza season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine (LAIV) for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014–15 season but not later than the 2015–16 season. Information regarding issues related to influenza vaccination not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations…

The report includes the preferential recommendation to use LAIV in healthy children 2 through 8 years of age when the nasal spray flu vaccine is immediately available and if the child has no contraindications or precautions to that vaccine. However, if the nasal spray vaccine is not immediately available, children in this age group should get the flu shot (IIV). Vaccination should not be delayed to obtain the nasal spray flu vaccine.

The complete article with 2014-15 influenza vaccination recommendations can be found at .

2014-15 Influenza Vaccine Information Statements Now Available

On August 19, CDC issued two new influenza Vaccine Information Statements (VISs) for use during the 2014–15 influenza season. The VIS for inactivated influenza vaccine (IIV) is intended for use with all non-live virus formulations—trivalent, quadrivalent, cell-culture, recombinant, intradermal, and high-dose. The VIS for live attenuated intranasal influenza vaccine (LAIV) is intended for use when administering nasal-spray vaccine.

CDC updates its Vaccine Storage & Handling Toolkit

In May, CDC released an updated version of its Vaccine Storage & Handling Toolkit, originally published online in 2012. The toolkit is based on the recommendations of the Advisory Committee on Immunization Practices (ACIP), equipment manufacturers' product information, and studies from the National Institute for Scientific Technology. Here's a direct link to the updated PDF document.

The toolkit outlines best practice strategies and recommendations on the following topics:

On the toolkit web page, you'll also find related resources such as training materials, slide sets, and other helpful items.

Related Links

Ohio Pharmacists May Administer MMR Vaccine Effective June 9, 2014

As of June 9, 2014, trained Ohio pharmacists are able to administer measles, mumps and rubella (MMR) vaccine to persons 18 years of age and older. Pharmacists who administer the vaccine must meet the training requirements of Ohio Board of Pharmacy Rule 4729-5-36, and work under a physician-established protocol. OPA is working on a supplemental home-study course for pharmacists  whose immunization training program did not include training for measles, mumps and rubella disease/vaccine.

Guidance document on this rule change can be found at  Pharmacists Can Now Administer the Measles, Mumps, and Rubella (MMR) Vaccine PDF  (Revised June 9, 2014)

Zoster Prescription Requirement Ends May 22: 
Update Your Protocol

As of May 22, 2014, trained Ohio pharmacists are able to administer Zostavax (herpes zoster vaccine) without a prescription.  The patient receiving the vaccine must meet the age criteria listed in the FDA-approved labeling.  Pharmacists who administer the vaccine must meet the training requirements of Ohio Board of Pharmacy Rule 4729-5-36, and work under a physician-established protocol. 

Guidance document on this rule change can be found at

Pharmacists currently administering Zostavax need to update their protocol to delete the requirements for a patient-specific prescription and administration of the vaccine within 30 days of issuance of the prescription. 

For pharmacists who have completed a board-approved immunization training program and whose training did not include zoster vaccine, OPA’s home-study CE article Immunizations for Selected Vaccine-Preventable Diseases in Adults is approved as a supplemental course. 

To order this Home-Study CE, Click Here

Flu Vaccine News

Provider Information for 2013-14 Influenza--NEW

A "Provider Information" document to supplement the 2013-14 influenza VISs has been posted by the CDC and is now available.  This document summarizes information from the current ACIP influenza recommendations, and is intended as a quick reference for providers to use when discussing influenza vaccine with their patients, or answering patients' questions. It provides detailed information on topics dealt with more superficially on the influenza VISs themselves.

Key Points in the Latest Recommendations

• Routine annual influenza vaccination of all persons aged six (6) months and older continues to be recommended.

• 2013-14 U.S. trivalent influenza vaccines will contain an A/California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus.  Quadrivalent vaccines will include an additional vaccine virus, a B/Brisbane/60/2008-like virus.

• Several new, recently-licensed vaccines will be available for the 2013-14 season, and are acceptable alternatives to other licensed vaccines indicated for their respective age groups.

• Within approved indications and recommendations, no preferential recommendation is made for any type or brand of licensed influenza vaccine over another.

• In general, health-care providers should begin offering vaccination soon after vaccine becomes available, and if possible, by October.

Full information may be found at

HealthMap Vaccine Finder

HealthMap Vaccine Finder ( is a free, online service where users can search for locations offering flu vaccines, as well as other adult vaccines. This service partners with clinics, pharmacies, and health departments to provide accurate and up-to-date information about receiving the flu vaccine. 

In 2012, Google passed the baton to HealthMap when it retired Google Flu Vaccine Finder. If you previously provided data to Google Flu Vaccine Finder and would like to still be included in the list of vaccine providers, you will need to register and upload your location data to HealthMap.

Draft Immunization Protocols

OPA annually drafts adult immunization protocols in compliance with the Ohio State Board of Pharmacy’s rules.  Updated protocols for 2013 are now available. To purchase the protocol package, visit the Immunization section of the OPA website,

 “MLN Matters® Article #MM8433: Influenza Vaccine Payment Allowances - Annual Update for 2013-2014 Season.”

Advisory Committee on Immunization Practices—(ACIP)—United States, 2013-14 

IAC's screening checklists for vaccines have been updated

Immunization Action Coalition (IAC) recently updated and renamed the following checklists for vaccine contraindications.

  1. Screening Checklist for Contraindications to Inactivated Injectable Influenza Vaccination, (formerly titled "Screening Questionnaire for Inactivated Injectable Influenza Vaccination")
  2. Screening Checklist for Contraindications to Live Attenuated Intranasal Influenza Vaccination (formerly titled "Screening Questionnaire for Live Attenuated Intranasal Influenza Vaccination")
  3. Screening Checklist for Contraindications to Vaccines for Adults (formerly titled "Screening Questionnaire for Adult Immunization")

CDC makes important changes to its recommendations for vaccine storage and handling

CDC recently made several important changes to its recommendations for vaccine storage and handling. They are published in the document Interim Vaccine Storage and Handling Guidance. The introduction is reprinted below.

In response to recent scientific studies on equipment used for vaccine storage and a better understanding of best practices for vaccine storage and handling, the Centers for Disease Control and Prevention (CDC) is providing interim guidance on appropriate vaccine storage and handling practices. This guidance is intended for use by all public and private sector providers and, while recognizing that cost may be a barrier, we encourage practices to move toward implementing these recommendations as soon as possible. CDC is currently evaluating the most efficient and cost effective method to phase these recommendations in and more guidance is forthcoming.

With the goal of improving the way providers store and handle vaccines nationwide, several important changes have been made to previous recommendations issued by CDC, including:

1. Use of a biosafe glycol-encased probe or a similar temperature buffered probe rather than measurement of ambient air temperatures, and;
2. Use of digital data loggers with detachable probes that record and store temperature information at frequent programmable intervals for 24 hour temperature monitoring rather than non-continuous temperature monitoring, and;
3. Use of stand-alone refrigerator and stand-alone freezer units suitable for vaccine storage rather than combination (refrigerator+freezer) or other units not designed for storing fragile biologics, such as vaccines, and;
4. Discontinuing use of dorm-style or bar-style refrigerator/
freezers for ANY vaccine storage, even temporary storage, and;
5. Weekly review of vaccine expiration dates and rotation of vaccine stock

Related Links

“Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immuno­compromising Conditions:

Recommendation of the Advisory Committee on Immunization Practices (ACIP)”

On October 12, 2012 CDC published ACIP recommen­dations on use of PCV13 and PPSV23 vaccines in adults.  Adults with specified immunocompromising conditions who are eligible for pneumococcal vaccine should be vaccinated with PCV13 during their next pneumococcal vaccination opportunity.

Pneumococcal vaccine-naïve persons. ACIP recommends that adults aged ≥19 years with immunocompromising condi­tions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later (Table). Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19–64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose.

Previous vaccination with PPSV23. Adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who previously have received ≥1 doses of PPSV23 should be given a PCV13 dose ≥1 year after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.

To access the complete published CDC recommendations, see pages 816–819 of MMWR at

Recommendations for Influenza Vaccination, Persons with Egg Allergy and Use of Antivirals

The most current information for health care professionals regarding influenza vaccine recommendations (including persons with egg allergy), vaccine supply, and recommendations for using antiviral agents for influenza can be found on the CDC website at

Additional Updates:

< Back | Printer Friendly Page
Get OPA Events via RSS


 September 2014 
September 25, 2014

APhA's Diabetes Care Certificate Training Program for Pharmacists

OPA office- 2674 Federated Blvd., Columbus, OH 43235

September 26, 2014

Ohio Pharmacy Advocacy Forum

Northeast Ohio Medical University, University Hall, 4209 State Route 44, Rootstown, OH 44272

October 8, 2014

APhA's Delivering MTM Services: A Certificate Training Program for Pharmacists

OPA office- 2674 Federated Blvd., Columbus, OH 43235

October 29, 2014

Live Webinar: Required OSHA Training for Immunizing Pharmacists 2 p.m. & 6 p.m.

October 30, 2014

Live Webinar: Required OSHA Training for Immunizing Pharmacists 11 a.m.